01.05.15
Kinetic Concepts Inc. has negotiated a new distribution agreement with B. Braun Medical Inc. to be an exclusive provider of Prontosan Wound Irrigation Solution for use with V.A.C. VeraFlo Instillation Therapy in the United States.
V.A.C. VeraFlo Instillation Therapy is an integrated wound therapy that couples negative pressure wound therapy (NPWT) with automated volumetric instillation of topical wound treatment solutions. The programmable soak feature allows appropriate topical wound solutions to dwell in the wound for thorough contact, facilitating dilution and solubilization of infectious material and wound debris. This dwell time is offered exclusively by V.A.C. VeraFlo Therapy.
“As a supplier of advanced wound care products, we are dedicated to forming partnerships with companies such as B. Braun that can help us streamline the wound management process for clinicians and patients alike,” said Ron Silverman, senior vice president and chief medical officer of Acelity.
Based on customer feedback, the Prontosan Wound Irrigation Solution now will be available in 1,000 mL bottles with built-in hangers and cap adaptors that provide quick and simple attachment to the V.A.C. Ulta Negative Pressure Wound Therapy System. The partnership also allows Prontosan Wound Irrigation Solution to be ordered and stored alongside other V.A.C. VeraFlo Therapy disposables in a facility supply room instead of the pharmacy, Kinetic executives noted.
Data published by MedStar Georgetown University Hospital showed that adjunctive treatment with V.A.C. VeraFlo Therapy, using the V.A.C. Ulta Negative Pressure Wound Therapy System and the Prontosan Wound Irrigation Solution, demonstrated a statistically significant decrease in operating room (OR) visits, time to final surgical procedure and length of stay compared to traditional V.A.C. Negative Pressure Wound Therapy for patients with wounds that required serial surgical debridement and hospitalization. The study is the most systematic examination to date of the impact of V.A.C. VeraFlo Therapy with Prontosan Wound Irrigation Solution in the adjunctive treatment of infected wounds in an inpatient setting, Kinetic bigwigs claim. An additional randomized controlled trial utilizing V.A.C. VeraFlo Therapy with Prontosan is underway.
Acelity is a global wound care and regenerative medicine firm created by uniting three companies, Kinetic Concepts, Inc., LifeCell Corporation and Systagenix Wound Management, Limited. Headquartered in San Antonio, Texas, Acelity employs more than 5,500 people worldwide.
B. Braun Medical Inc. develops, manufactures, and markets infusion therapy and pain management products and services. The B.Braun Group of companies in the United States includes B.Braun, B.Braun Interventional Systems, Aesculap and CAPS. B.Braun's American headquarters is located in Bethlehem, Pa. The B.Braun Group employs more than 50,000 employees in more than 60 countries throughout the world.
V.A.C. VeraFlo Instillation Therapy is an integrated wound therapy that couples negative pressure wound therapy (NPWT) with automated volumetric instillation of topical wound treatment solutions. The programmable soak feature allows appropriate topical wound solutions to dwell in the wound for thorough contact, facilitating dilution and solubilization of infectious material and wound debris. This dwell time is offered exclusively by V.A.C. VeraFlo Therapy.
“As a supplier of advanced wound care products, we are dedicated to forming partnerships with companies such as B. Braun that can help us streamline the wound management process for clinicians and patients alike,” said Ron Silverman, senior vice president and chief medical officer of Acelity.
Based on customer feedback, the Prontosan Wound Irrigation Solution now will be available in 1,000 mL bottles with built-in hangers and cap adaptors that provide quick and simple attachment to the V.A.C. Ulta Negative Pressure Wound Therapy System. The partnership also allows Prontosan Wound Irrigation Solution to be ordered and stored alongside other V.A.C. VeraFlo Therapy disposables in a facility supply room instead of the pharmacy, Kinetic executives noted.
Data published by MedStar Georgetown University Hospital showed that adjunctive treatment with V.A.C. VeraFlo Therapy, using the V.A.C. Ulta Negative Pressure Wound Therapy System and the Prontosan Wound Irrigation Solution, demonstrated a statistically significant decrease in operating room (OR) visits, time to final surgical procedure and length of stay compared to traditional V.A.C. Negative Pressure Wound Therapy for patients with wounds that required serial surgical debridement and hospitalization. The study is the most systematic examination to date of the impact of V.A.C. VeraFlo Therapy with Prontosan Wound Irrigation Solution in the adjunctive treatment of infected wounds in an inpatient setting, Kinetic bigwigs claim. An additional randomized controlled trial utilizing V.A.C. VeraFlo Therapy with Prontosan is underway.
Acelity is a global wound care and regenerative medicine firm created by uniting three companies, Kinetic Concepts, Inc., LifeCell Corporation and Systagenix Wound Management, Limited. Headquartered in San Antonio, Texas, Acelity employs more than 5,500 people worldwide.
B. Braun Medical Inc. develops, manufactures, and markets infusion therapy and pain management products and services. The B.Braun Group of companies in the United States includes B.Braun, B.Braun Interventional Systems, Aesculap and CAPS. B.Braun's American headquarters is located in Bethlehem, Pa. The B.Braun Group employs more than 50,000 employees in more than 60 countries throughout the world.